228 related articles for article (PubMed ID: 24754646)
1. Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis.
Curtis JR; Schabert VF; Yeaw J; Korn JR; Quach C; Harrison DJ; Yun H; Joseph GJ; Collier D
J Med Econ; 2014 Aug; 17(8):555-66. PubMed ID: 24754646
[TBL] [Abstract][Full Text] [Related]
2. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
[TBL] [Abstract][Full Text] [Related]
3. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
Curtis JR; Chastek B; Becker L; Quach C; Harrison DJ; Yun H; Joseph GJ; Collier DH
J Manag Care Spec Pharm; 2015 Apr; 21(4):318-29. PubMed ID: 25803765
[TBL] [Abstract][Full Text] [Related]
4. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
[TBL] [Abstract][Full Text] [Related]
5. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis.
Popp RA; Rascati K; Davis M; Patel U
Pharmacotherapy; 2018 Feb; 38(2):172-180. PubMed ID: 29197108
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
[TBL] [Abstract][Full Text] [Related]
7. Two-year adherence and costs for biologic therapy for rheumatoid arthritis.
Stolshek BS; Wade S; Mutebi A; De AP; Wade RL; Yeaw J
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP315-SP321. PubMed ID: 30020744
[TBL] [Abstract][Full Text] [Related]
8. Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study.
Gu T; Shah N; Deshpande G; Tang DH; Eisenberg DF; Harrison DJ
J Health Econ Outcomes Res; 2016; 3(2):122-131. PubMed ID: 37663319
[No Abstract] [Full Text] [Related]
9. Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data.
Gharaibeh M; Bonafede M; McMorrow D; Hernandez EJM; Stolshek BS
J Manag Care Spec Pharm; 2020 Aug; 26(8):1039-1049. PubMed ID: 32715967
[TBL] [Abstract][Full Text] [Related]
10. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
11. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
12. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y
Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
[TBL] [Abstract][Full Text] [Related]
14. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
[TBL] [Abstract][Full Text] [Related]
15. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting.
Meissner B; Trivedi D; You M; Rosenblatt L
J Med Econ; 2014 Apr; 17(4):259-65. PubMed ID: 24575891
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.
Yang M; Galebach PJ; Signorovitch JE; Garg V
Clin Exp Rheumatol; 2017; 35(5):791-798. PubMed ID: 28339358
[TBL] [Abstract][Full Text] [Related]
17. Cost of biologic treatment persistence or switching in rheumatoid arthritis.
Gu T; Mutebi A; Stolshek BS; Tan H
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP338-SP345. PubMed ID: 30020745
[TBL] [Abstract][Full Text] [Related]
18. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
Chastek B; Becker LK; Chen CI; Mahajan P; Curtis JR
J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149
[TBL] [Abstract][Full Text] [Related]
20. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
